Intervention with Therapeutic Agents, Understanding the Path to Remission in Type 2 Diabetes: part 1

• Shuai Hao ^[1] ; Guillermo E. Umpierrez ^[1] ; Tanicia Daley ^[1] ; Priyathama Vellanki ^[1]
  1. [1] Emory University

     Emory University

     Estados Unidos

     
• Localización: Endocrinology and metabolism clinics of North America, ISSN 0889-8529, Vol. 52, Nº. 1, 2023, págs. 27-38
• Idioma: inglés
• Texto completo no disponible (Saber más ...)
• Resumen

  • Type 2 diabetes is characterized by progressive decline in pancreatic β-cell function. Studies in adult subjects with newly diagnosed type 2 diabetes have reported that intensive insulin therapy followed by various antihyperglycemic medications can delay β-cell decline. However, this improvement is lost after cessation of therapy. In contrast, youth with type 2 diabetes experience a more rapid loss in β-cell function compared with adults and have loss of β-cell function despite being on insulin and other antihyperglycemic medications. In part one of this two-part review, we discuss studies aiming to achieve diabetes remission with insulin and oral antidiabetic medications.